Related Experiment Video

Updated: Jun 8, 2026

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography
06:09

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography

Published on: July 21, 2023

[The detection and clinical significance of hepatic fibrosis index]

Chun-Hai Xu1, Dong-Mei Meng, Shu-Lan Lv

  • 1The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi = Zhonghua Shiyan He Linchuang Bingduxue Zazhi = Chinese Journal of Experimental and Clinical Virology
|September 21, 2010
PubMed

Insights

Serum hyaluronic acid (HA), laminin (LN), type IV collagen (IV-C), and procollagen III peptide (PC III) levels correlate with liver fibrosis in chronic hepatitis patients. These markers aid in diagnosing liver fibrosis severity.

Area of Science:

  • Biochemistry
  • Hepatology
  • Diagnostic Markers

Context:

  • Chronic hepatitis is a significant global health concern, often leading to liver fibrosis.
  • Accurate assessment of liver fibrosis is crucial for patient management and treatment decisions.

Purpose:

  • To investigate the relationship between serum levels of hyaluronic acid (HA), laminin (LN), type IV collagen (IV-C), and procollagen III peptide (PC III) and the degree of liver fibrosis in patients with chronic hepatitis.
  • To evaluate the diagnostic utility of these serum markers in assessing liver fibrosis.

Summary:

  • Serum HA and IV-C levels demonstrated parallel changes across different stages of chronic hepatitis.
  • Serum LN and PC III levels showed concordance with specific pathological periods of fibrosis, with PC III approaching normal levels before the G4 stage.
  • Significantly elevated levels of HA, LN, IV-C, and PC III were observed in chronic hepatitis patients compared to healthy controls.
  • The study concludes that serum HA, LN, IV-C, and PC III are valuable indicators that correlate with the degree of liver fibrosis and can aid in the clinical diagnosis of chronic hepatitis.

Impact:

  • Provides a non-invasive method for assessing liver fibrosis, potentially reducing the need for liver biopsies.
  • Offers valuable biochemical markers for monitoring disease progression and treatment efficacy in chronic hepatitis.
  • Enhances the understanding of the dynamic changes in extracellular matrix components during liver fibrogenesis.
Abstract

More Related Videos

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...